{Reference Type}: Journal Article
{Title}: Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.
{Author}: Fumet JD;Lardenois E;Ray-Coquard I;Harter P;Joly F;Canzler U;Truntzer C;Tredan O;Liebrich C;Lortholary A;Pissaloux D;Leary A;Pfisterer J;Eeckhoutte A;Hilpert F;Fabbro M;Caux C;Alexandre J;Houlier A;Sehouli J;Sohier E;Kimmig R;Dubois B;Spaeth D;Treilleux I;Frenel JS;Herwig U;Le Saux O;Bendriss-Vermare N;du Bois A;
{Journal}: Cancers (Basel)
{Volume}: 14
{Issue}: 5
{Year}: Feb 2022 25
{Factor}: 6.575
{DOI}: 10.3390/cancers14051189
{Abstract}: BACKGROUND: Following disappointing results with PD-1/PD-L1 inhibitors in ovarian cancer, it is essential to explore other immune targets. The aim of this study is to describe the tumor immune microenvironment (TME) according to genomic instability in high grade serous ovarian carcinoma (HGSOC) patients receiving primary debulking surgery followed by carboplatin-paclitaxel chemotherapy +/- nintedanib.
METHODS: 103 HGSOC patients' tumor samples from phase III AGO-OVAR-12 were analyzed. A comprehensive analysis of the TME was performed by immunohistochemistry on tissue microarray. Comparative genomic hybridization was carried out to evaluate genomic instability signatures through homologous recombination deficiency (HRD) score, genomic index, and somatic copy number alterations. The relationship between genomic instability and TME was explored.
RESULTS: Patients with high intratumoral CD3+ T lymphocytes had longer progression-free survival (32 vs. 19.6 months, p = 0.009) and overall survival (OS) (median not reached). High HLA-E expression on tumor cells was associated with a longer OS (median OS not reached vs. 52.9 months, p = 0.002). HRD profile was associated with high HLA-E expression on tumor cells and an improved OS. In the multivariate analysis, residual tumor, intratumoral CD3, and HLA-E on tumor cells were more predictive than other parameters.
CONCLUSIONS: Our results suggest HLA-E/CD94-NKG2A/2C is a potential immune target particularly in the HRD positive ovarian carcinoma subgroup.